WX-UK1

DB05476InvestigationalSmall molecule

WX-UK1 is a 3-amidinophenylalanine-based non-cytotoxic small molecule that belongs to a new class of drugs. In animal models, WX-UK1 blocks tumor cell invasion, metastasis and primary tumor growth by inhibiting... Independent studies show that administration of Wx-UK1 resulted in a decrease of tumor cell invasion, suggesting its efficacy as a an adjuvant antimetastatic therapy of carcinomas.

Mechanism: Activity at urokinase plasminogen activator receptors (uPAR) results in inhibition of uPA system.
Curator reviewed
Primary indication: Investigated for use/treatment in solid tumors.Curator reviewed
Formula / weight: C₃₂H₄₈ClN₅O₅S · 650.28 g/mol (avg)
Code names: WX-UK1

Resolves to

Compound

UNIIUJ925Q0P3BCAS255374-84-6PubChem9939426

Structure

InChIKeyFMHIVIJVVYYSRN-JCOPYZAKSA-NSMILESCl.CCOC(=O)N1CCN(CC1)C(=O)[C@H](CC1=CC=CC(=C1)C(N)=N)NS(=O)(=O)C1=C(C=C(C=C1C(C)C)C(C)C)C(C)C

Targets

Q03405PLAURP00749PLAU

What you can answer from here — as of April 23, 2025

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with WX-UK1, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account